Literature DB >> 24220225

Evaluation of the effects of different culture media on the myogenic differentiation potential of adipose tissue- or bone marrow-derived human mesenchymal stem cells.

Jens Stern-Straeter1, Gabriel Alejandro Bonaterra, Stephanie Juritz, Richard Birk, Ulrich Reinhart Goessler, Karen Bieback, Peter Bugert, Johannes Schultz, Karl Hörmann, Ralf Kinscherf, Anne Faber.   

Abstract

The creation of functional muscles/muscle tissue from human stem cells is a major goal of skeletal muscle tissue engineering. Mesenchymal stem cells (MSCs) from fat/adipose tissue (AT-MSCs), as well as bone marrow (BM-MSCs) have been shown to bear myogenic potential, which makes them candidate stem cells for skeletal muscle tissue engineering applications. The aim of this study was to analyse the myogenic differentiation potential of human AT-MSCs and BM-MSCs cultured in six different cell culture media containing different mixtures of growth factors. The following cell culture media were used in our experiments: mesenchymal stem cell growth medium (MSCGM)™ as growth medium, MSCGM + 5-azacytidine (5-Aza), skeletal muscle myoblast cell growth medium (SkGM)-2 BulletKit™, and 5, 30 and 50% conditioned cell culture media, i.e., supernatant of human satellite cell cultures after three days in cell culture mixed with MSCGM. Following the incubation of human AT-MSCs or BM-MSCs for 0, 4, 8, 11, 16 or 21 days with each of the cell culture media, cell proliferation was measured using the alamarBlue® assay. Myogenic differentiation was evaluated by quantitative gene expression analyses, using quantitative RT-PCR (qRT-PCR) and immunocytochemical staining (ICC), using well-defined skeletal markers, such as desmin (DES), myogenic factor 5 (MYF5), myosin, heavy chain 8, skeletal muscle, perinatal (MYH8), myosin, heavy chain 1, skeletal muscle, adult (MYH1) and skeletal muscle actin-α1 (ACTA1). The highest proliferation rates were observed in the AT-MSCs and BM-MSCs cultured with SkGM-2 BulletKit medium. The average proliferation rate was higher in the AT-MSCs than in the BM-MSCs, taking all six culture media into account. qRT-PCR revealed the expression levels of the myogenic markers, ACTA1, MYH1 and MYH8, in the AT-MSC cell cultures, but not in the BM-MSC cultures. The muscle-specific intermediate filament, DES, was only detected (by ICC) in the AT-MSCs, but not in the BM-MSCs. The strongest DES expression was observed using the 30% conditioned cell culture medium. The detection of myogenic markers using different cell culture media as stimuli was only achieved in the AT-MSCs, but not in the BM-MSCs. The strongest myogenic differentiation, in terms of the markers examined, was induced by the 30% conditioned cell culture medium.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24220225     DOI: 10.3892/ijmm.2013.1555

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  12 in total

1.  BMP9-induced osteogenic differentiation is partially inhibited by miR-30a in the mesenchymal stem cell line C3H10T1/2.

Authors:  Ruyi Zhang; Yaguang Weng; Baolin Li; Yingjiu Jiang; Shujuan Yan; Fang He; Xiaoqing Chen; Fang Deng; Jing Wang; Qiong Shi
Journal:  J Mol Histol       Date:  2015-07-24       Impact factor: 2.611

Review 2.  [New perspectives in skeletal muscle tissue engineering].

Authors:  J Stern-Straeter; K Hörmann
Journal:  HNO       Date:  2014-06       Impact factor: 1.284

3.  Chromosomal Translocation t(5;12)(p13;q14) Leading to Fusion of High-mobility Group AT-hook 2 Gene With Intergenic Sequences From Chromosome Sub-Band 5p13.2 in Benign Myoid Neoplasms of the Breast: A Second Case.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Hanne Regine Hognestad; Ingvild Lobmaier; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

4.  Effect of MRI tags: SPIO nanoparticles and 19F nanoemulsion on various populations of mouse mesenchymal stem cells.

Authors:  Ghulam Muhammad; Anna Jablonska; Laura Rose; Piotr Walczak; Miroslaw Janowski
Journal:  Acta Neurobiol Exp (Wars)       Date:  2015       Impact factor: 1.579

5.  The Mutual Interactions between Mesenchymal Stem Cells and Myoblasts in an Autologous Co-Culture Model.

Authors:  Agnieszka Kulesza; Anna Burdzinska; Izabela Szczepanska; Weronika Zarychta-Wisniewska; Beata Pajak; Kamil Bojarczuk; Bartosz Dybowski; Leszek Paczek
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

Review 6.  Patient-Specific Age: The Other Side of the Coin in Advanced Mesenchymal Stem Cell Therapy.

Authors:  Magdalena M Schimke; Sabrina Marozin; Günter Lepperdinger
Journal:  Front Physiol       Date:  2015-12-02       Impact factor: 4.566

7.  Myogenic differentiation of primary myoblasts and mesenchymal stromal cells under serum-free conditions on PCL-collagen I-nanoscaffolds.

Authors:  Aijia Cai; Moritz Hardt; Paul Schneider; Rafael Schmid; Claudia Lange; Dirk Dippold; Dirk W Schubert; Anja M Boos; Annika Weigand; Andreas Arkudas; Raymund E Horch; Justus P Beier
Journal:  BMC Biotechnol       Date:  2018-11-26       Impact factor: 2.563

8.  Supplementation with IL-6 and Muscle Cell Culture Conditioned Media Enhances Myogenic Differentiation of Adipose Tissue-Derived Stem Cells through STAT3 Activation.

Authors:  Eunhui Seo; Hwansu Kang; Oh-Kyung Lim; Hee-Sook Jun
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

9.  Sex-Specific Transcriptome Differences in Human Adipose Mesenchymal Stem Cells.

Authors:  Eva Bianconi; Raffaella Casadei; Flavia Frabetti; Carlo Ventura; Federica Facchin; Silvia Canaider
Journal:  Genes (Basel)       Date:  2020-08-08       Impact factor: 4.096

Review 10.  Bringing cultured meat to market: Technical, socio-political, and regulatory challenges in cellular agriculture.

Authors:  Neil Stephens; Lucy Di Silvio; Illtud Dunsford; Marianne Ellis; Abigail Glencross; Alexandra Sexton
Journal:  Trends Food Sci Technol       Date:  2018-08       Impact factor: 12.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.